Method of treating chronic obstructive pulmonary disease (CPD) with verproside

US10172816B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10172816-B2
Application numberUS-201615384302-A
CountryUS
Kind codeB2
Filing dateDec 19, 2016
Priority dateApr 10, 2013
Publication dateJan 8, 2019
Grant dateJan 8, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of treating chronic obstructive pulmonary disease (COPD) in a mammal comprising administering a therapeutically effective amount of verproside to the mammal suffering from chronic obstructive pulmonary disease (COPD). 2. A method of treating chronic obstructive pulmonary disease (COPD) in a mammal comprising administering a composition comprising a therapeutically effective amount of verproside and a pharmaceutically acceptable carrier or excipient to the mammal suffering from chronic obstructive pulmonary disease (COPD).

Assignees

Inventors

Classifications

  • Drugs for disorders of the respiratory system · CPC title

  • Plant extracts, their artificial duplicates or their derivatives · CPC title

  • having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

  • Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine · CPC title

  • Scrophulariaceae (Figwort family) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10172816B2 cover?
A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic r…
Who is the assignee on this patent?
Yungjin Pharmaceutical Co Ltd, Korea Res Inst Bioscience & Biotechnology
What technology area does this patent fall under?
Primary CPC classification A61K31/192. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).